The HBP1 Knockout A-549 Polyclonal Cells constitute a pool of A-549 epithelial cells subjected to CRISPR/Cas9-mediated disruption of the HBP1 gene, producing a heterogeneous polyclonal knockout population. This product is designed to ablate HBP1 expression, enabling loss-of-function studies without involving a single-cell-derived clonal isolate. The polyclonal format captures a distribution of gene-editing events, providing a robust model for population-level analyses relevant to cancer biology and signal transduction research.
The parental A-549 cell line originates from a human lung adenocarcinoma and is extensively employed as an in vitro model for non-small cell lung cancer (NSCLC). These adherent epithelial cells retain key characteristics of the tumor of origin and are widely utilized to investigate oncogenic signaling, drug responses, and tumor cell behavior. The A-549 background offers a clinically relevant context for studying the impact of HBP1 loss in lung adenocarcinoma.
HBP1 encodes a transcriptional repressor that integrates inputs from the p38 MAPK cascade and the canonical Wnt pathway. Upon activation, p38 MAPK phosphorylates HBP1, enhancing its interaction with cofactors such as RB1 and HDAC1 and promoting assembly with TCF/LEF transcription factors at Wnt-responsive promoters. Through these complexes, HBP1 suppresses the expression of cell cycle drivers including CCND1 (cyclin D1) and MYC, while also influencing the CDKN1A (p21) axis. Wnt ligands, Frizzled receptors, and Dishevelled upstream of ??-catenin converge on TCF/LEF, where HBP1 acts as a repressor, and TGF-?? also participates in its context-dependent regulation. Thus, HBP1 serves as a critical node coordinating growth-inhibitory and differentiation signals.
Disruption of HBP1 in A-549 lung adenocarcinoma cells is predicted to relieve transcriptional repression of its targets, removing a key brake on cell cycle progression. This loss-of-function model may exhibit enhanced proliferation, altered responses to mitogenic Wnt ligands, and modified sensitivity to TGF-?? or p38 MAPK pathway inhibitors. Consequently, these polyclonal knockout cells facilitate the dissection of HBP1-dependent tumor-suppressive mechanisms within a NSCLC-relevant setting and help elucidate how derepression of CCND1 and MYC contributes to adenocarcinomic phenotypes.
Researchers can apply this product in a variety of experimental workflows, including western blotting and RT-qPCR to confirm target-gene deregulation, flow-cytometric cell cycle profiling, MTT and colony formation assays to measure proliferative capacity, and TCF/LEF luciferase reporter systems to probe Wnt transcriptional output. Transcriptomic approaches such as RNA-seq and functional assays like migration and invasion tests further expand the scope. This knockout model supports investigations into lung cancer proliferation, senescence bypass, apoptosis resistance, and drug sensitivity. For further technical information or to discuss custom applications, please contact Ascent Research.
